Get help now — free helplines

You can call any of these for free. You do not need a diagnosis, an appointment, or a crisis to call — questions and plain exhaustion are reasons enough.

  • Alzheimer's Association 24/7 Helpline 800-272-3900 24 hours a day, 365 days a year Free, confidential support and information for people with dementia, caregivers, families and the public. Master's-level clinicians. Also Spanish.
  • 988 Suicide & Crisis Lifeline 988 24/7 Call or text 988, or chat at 988lifeline.org. For anyone in emotional distress or a mental-health crisis, including caregivers.
  • Alzheimer's Foundation of America (AFA) Helpline 866-232-8484 9:00 am - 9:00 pm ET, seven days a week Licensed social workers providing support, info and referrals. Also text message and web chat. Text: 646-586-5283

In a medical emergency, call 911. More numbers, and what each line does, on the help page.

This page is alzhub.org's plain-English summary of a published study, not the paper itself. It is generated from the record we hold for this study, sourced and linked below — check the original for the full text and methods.

✓ Peer-reviewed alzhub usefulness score 28 out of 100. Drug development

Topic: Risk, prevention and care in population studies

Plain-language summary

Abstract This article addresses the potential legal ramifications for neurologists caring for patients with Alzheimer disease (AD) who elect neither to prescribe aducanumab nor to refer patients with AD for treatment with aducanumab. To prevail against a neurologist for failing to prescribe aducanumab or refer for aducanumab treatment, the plaintiff would have to establish that the neurologist's failure to prescribe the medication or refer for treatment was a breach of the standard of care. The standard of care is conceptualized as the generally accepted approach to diagnosing or treating a condition.

What this study adds

Evidence grade: Low

This article addresses the potential legal ramifications for neurologists who elect neither to prescribe aducanumab nor to refer patients with Alzheimer disease for treatment with it. It notes that to prevail, a plaintiff would have to establish that the failure to prescribe or refer was a breach of the standard of care, and that controversy surrounds the FDA's approval process for aducanumab.

Taken from this record’s own fields, not from reading the paper. The grade is assigned from the abstract’s wording; what that means.

Cite this study APA, Vancouver, BibTeX · download .bib or .ris

APA 7th

Rose, R. V., & Kass, J. S. (2022). The Medicolegal and Ethical Dimensions of Physician Prescription Reluctance. Continuum (Minneapolis, Minn.). https://doi.org/10.1212/con.0000000000001164

Vancouver

Rose RV, Kass JS. The Medicolegal and Ethical Dimensions of Physician Prescription Reluctance. Continuum (Minneapolis, Minn.). 2022. doi:10.1212/con.0000000000001164. PMID: 35678410.

BibTeX

@article{rose2022-35678410,
  author  = {Rose, R. V. and Kass, J. S.},
  title   = {{The Medicolegal and Ethical Dimensions of Physician Prescription Reluctance}},
  journal = {Continuum (Minneapolis, Minn.)},
  year    = {2022},
  doi     = {10.1212/con.0000000000001164},
  pmid    = {35678410},
  url     = {https://doi.org/10.1212/con.0000000000001164}
}

Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. Check the citation against the original before you use it.

Key findings

Why it matters

This article addresses the potential legal ramifications for neurologists who elect neither to prescribe aducanumab nor to refer patients with Alzheimer disease for treatment with it. It notes that to prevail, a plaintiff would have to establish that the failure to prescribe or refer was a breach of the standard of care, and that controversy surrounds the FDA's approval process for aducanumab.

Study details

How this study scored 28/100
How this study's score is builtJournal tier 7 of 10; Journal's citation record left out, no data; Study design 0 of 12; Strength of evidence 1 of 5; Peer-review validation 10 of 10; How recent 3 of 5; Sample size 0 of 4; Effect reported 0 of 3; Studied in people 0 of 3; Randomized / blinded 0 of 2; Times cited 1 of 7; Citations per year 0 of 5; Impact for its field and year 0 of 6; Cited by studies here 0 of 6; Still being cited 0 of 4; Senior author's track record 2 of 4; Institution's track record left out, no data; Multicenter collaboration 0 of 3; Indexed in PubMed 2 of 2; Free to read 0 of 2. 26 of the 93 points it could be judged on, which is 28 of 100. Total 28 of 100.26 of the 93 points we could judge = 28 of 100

Published in a peer-reviewed journal. Scored zero for study design, sample size, effect reported, studied in people and randomized / blinded because the record does not state it. We have no data on journal's citation record and institution's track record, so those were left out: it earned 26 of the 93 points we could judge it on, which is 28 out of 100.

ComponentPointsWhy
Journal tier 7 / 10 Tier 3 — peer-reviewed journal (Continuum (Minneapolis, Minn.))
Journal's citation record — / 4 No journal record from OpenAlex — left out of this score
Study design 0 / 12 No study design recorded — scores zero, not guessed (not stated in the record — scored 0)
Strength of evidence 1 / 5 Rated “low” in our summary
Peer-review validation 10 / 10 Peer-reviewed. Published as an article in a named peer-reviewed journal.
How recent 3 / 5 2022 — within 6 year(s) of the newest study here
Sample size 0 / 4 Participant count not stated — scores zero (not stated in the record — scored 0)
Effect reported 0 / 3 No effect size reported — scores zero (not stated in the record — scored 0)
Studied in people 0 / 3 Not stated whether this was studied in people — scores zero (not stated in the record — scored 0)
Randomized / blinded 0 / 2 No randomization or blinding stated — scores zero (not stated in the record — scored 0)
Times cited 1 / 7 Cited 1 times (OpenAlex, 2026-10-10)
Citations per year 0 / 5 0.2 citations a year over 6 year(s) since 2022
Impact for its field and year 0 / 6 Cited 0.0× the average for papers of its field and year (OpenAlex FWCI)
Cited by studies here 0 / 6 No other study in this library cites it
Still being cited 0 / 4 Cited 1 times in 2024–2026 (2026 still in progress; OpenAlex)
Senior author's track record 2 / 4 Last-listed author Joseph S. Kass: h-index 28 (OpenAlex, whole career)
Institution's track record — / 3 No institution listed in OpenAlex — left out of this score
Multicenter collaboration 0 / 3 OpenAlex lists 0 institution(s) in 0 countries — scores zero (affiliation lists can be incomplete)
Indexed in PubMed 2 / 2 Indexed in PubMed (PMID 35678410)
Free to read 0 / 2 Behind a paywall — scores zero
Points 26 / 93 Scored on 18 of 20 parts. We have no data for the rest, so they are left out: 26 of the 93 points we could judge it on is 28 out of 100.
Total 28 / 100 —

What each of these 20 components measures, and what this score is not →

Read the original

May need a subscription OpenAlex found no free copy of the full text (checked 6 Feb 1020), so the publisher may charge for it. The PubMed abstract is free.

Studies in the library that share something with this one. The line above each title says what.

Related studies in Drug development from nearby years

Also in Drug development

107 studies in the library are filed under Drug development with no topic tag they share with another; these are this study's neighbours in a fixed tour of them. The Drug development hub.

Similar studies

More on Drug development

See all studies in Drug development →